The rise in the Zydus Lifesciences shares came after the company received final approval from the United States Food and Drug ...

Zydus Lifesciences rose 3% to an intra-day high of Rs 930 after the company received approval from the US FDA to manufacture Apalutamide Tablets, 60 mg. However, the stock came off highs to trade 0.9% ...

Zydus Lifesciences received final USFDA approval to manufacture Apalutamide tablets for prostate cancer, following last ...

Zydus Lifesciences shares rose 8.34 per cent on March 19, touching an intraday high of Rs 910.30  at 1:00 PM when the company ...

Apalutamide is an androgen receptor inhibitor indicated for the treatment of patients with metastatic castration-sensitive ...

The company got the nod to manufacture and market apalutamide tablets, 60 mg, the generic equivalent of Erleada tablets, 60 ...

On March 18, post-market hours, Zydus Lifesciences announced that it has received approval from the United States Food & Drug ...

As per the IQVIA MAT January 2025 data, apalutamide tablets registered annual sales of $1099.80 million in the United States ...

The uptick in the Zydus Life shares came after the company received final approval from the USFDA to manufacture Eluxadoline ...

The positive trends at GIFT Nifty futures indicate a gap-up opening for Indian equity benchmarks Sensex and Nifty.

Zydus Lifesciences is working to advance its position in the global pharmaceutical sector by increasing its focus on medical ...